The recovery of lost intellectual data opens door to new opportu

As the court ruled in the favor of Hemostemix and all the intellectual property relating to ACP-01 was returned to Hemostemix, the management is independent to cultivate important business development strategies as well as it enables the extraction of phase 2 clinical trial data.